Biomerica Expands CDMO Services to Capture Growing Diagnostic Development Market
核心洞察
Biomerica announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to meet accelerating market demand from biotechnology and diagnostic companies.
The company leverages over 40 years of expertise in assay development, manufacturing, and regulatory compliance to provide end-to-end support from concept through commercial manufacturing.
Services include comprehensive capabilities spanning lateral flow assays, ELISA tests, antibody development, and manufacturing assembly, backed by ISO 13485 certification and FDA-registered cGMP facilities.
Biomerica, Inc. (Nasdaq: BMRA) announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to meet accelerating market demand from biotechnology and diagnostic companies worldwide. The global provider of advanced medical diagnostic solutions is enhancing its capabilities to provide greater value and reliability across the entire product development lifecycle for diagnostic innovators.
With more than 40 years of expertise in assay development, manufacturing, and regulatory compliance, Biomerica is increasingly being approached by biotechnology and diagnostic companies seeking a proven partner to accelerate innovation and scale manufacturing. The company's CDMO services are a growing contributor to revenue and represent an opportunity for growth.
"Over the past several years, we have experienced a meaningful increase in interest from both large diagnostic organizations to smaller innovative organizations who are seeking to leverage our specialized development expertise, regulatory compliance track record, and manufacturing capabilities," said Zack Irani, CEO of Biomerica. "We are now formalizing and expanding these CDMO services, providing clients with end-to-end support from concept through commercial manufacturing."
Comprehensive Service Portfolio
Biomerica's CDMO services enable partners to reduce timelines, streamline production, and ensure reliable, high-quality outcomes in lateral flow, point-of-care diagnostics, ELISA tests, and Multiplex ELISA assays. The services span the entire development lifecycle across five key areas:
Assay Development & Custom Solutions include custom Lateral Flow Assay (LFA), ELISA and Multiplex ELISA development, companion diagnostics, and 96-well plate coating capabilities.
Antibody & Reagent Services encompass HRP antibody conjugation, biotinylation, and colloidal gold antibody conjugation processes.
Recombinant Antibody Development focuses on developing high-quality recombinant antibodies and stable cell lines within weeks.
Manufacturing & Assembly operations cover lateral flow cassette assembly, automated ELISA plate coating, custom lyophilization, and automated reagent filling, labeling, and capping.
Supply Chain & Technology Transfer services provide global sourcing and qualification of critical raw materials, full technology transfer support, and seamless scale-up into commercial production.
Enhanced Market Positioning
As part of this initiative, Biomerica has updated its corporate website to prominently feature its CDMO capabilities, making it easier for new partners to understand the company's expanded service offering. The updated site showcases service descriptions and resources to further support collaboration with innovators.
Backed by ISO 13485 certification, CE-mark expertise, and an FDA registered cGMP manufacturing facility, Biomerica ensures regulatory compliance and quality standards at every stage. The company is well-positioned to capture the growing demand for outsourced diagnostic development and production. By providing integrated solutions, Biomerica enables partners to reduce development timelines, de-risk regulatory hurdles, and scale products more efficiently.
Strategic Focus on Diagnostics
Biomerica is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care and in hospital/clinical laboratories for detection and treatment of medical conditions and diseases. The company's products are designed to enhance health and well-being while reducing total healthcare costs.
Biomerica primarily focuses on gastrointestinal and inflammatory diseases (搜索) where the company has multiple diagnostic and therapeutic products in development. The expanding CDMO services provide pharmaceutical, biotechnology, and diagnostic companies with trusted solutions for assay development and scalable manufacturing, representing a strategic growth avenue for the organization.